RESULTS: We observed significantly decreased Alu methylation levels in type 2 DM patients compared with normal (p = 0.0462). Moreover, our findings demonstrated changes in Alu hypomethylation over a follow-up period within the same individuals (p < 0.0001). A reduction in Alu methylation was found in patients with increasing HbA1c levels (p = 0.0013) and directly correlated with increased HbA1c levels in type 2 DM patients (r = -0.2273, p = 0.0387).
CONCLUSIONS: Alu methylation in type 2 DM patients progressively decreases with increasing HbA1c levels. This observation suggests a potential association between Alu hypomethylation and the underlying molecular mechanisms of elevated blood glucose. Furthermore, monitoring Alu methylation levels may serve as a valuable biomarker for assessing the clinical outcomes of type 2 DM.
结果:我们观察到2型DM患者的Alu甲基化水平明显低于正常(p=0.0462)。此外,我们的研究结果表明,在同一个体的随访期内,Alu低甲基化发生了变化(p<0.0001).在HbA1c水平升高的患者中发现Alu甲基化降低(p=0.0013),并且与2型DM患者中HbA1c水平升高直接相关(r=-0.2273,p=0.0387)。
结论:2型DM患者的Alu甲基化随着HbA1c水平的升高而逐渐降低。该观察表明Alu低甲基化与血糖升高的潜在分子机制之间存在潜在关联。此外,监测Alu甲基化水平可作为评估2型DM临床结局的有价值的生物标志物.